Fu Chunyun, Xie Bobo, Zhang Shujie, Wang Jin, Luo Shiyu, Zheng Haiyang, Su Jiasun, Hu Xuyun, Chen Rongyu, Fan Xin, Luo Jingsi, Gu Xuefan, Chen Shaoke
Department of Genetic Metabolism, Children's Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China Guangxi Center for Birth Defects Research and Prevention, Nanning, People's Republic of China.
Endocrinology and Genetic Metabolism of Institute for Pediatric Research, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
BMJ Open. 2016 May 12;6(5):e010719. doi: 10.1136/bmjopen-2015-010719.
Defects in the human thyroid peroxidase (TPO) gene are reported to be one of the causes of congenital hypothyroidism (CH) due to dyshormonogenesis. The aim of this study was to examine the TPO mutation spectrum and prevalence among patients with CH in the Guangxi Zhuang Autonomous Region of China and to define the relationships between TPO genotypes and clinical phenotypes.
Blood samples were collected from 192 patients with CH in the Guangxi Zhuang Autonomous Region, China and genomic DNA was extracted from peripheral blood leucocytes. All exons of the 10 common CH-associated genes including TPO together with their exon-intron boundaries were screened by next-generation sequencing (NGS). The effect of the novel TPO mutation was investigated by 'in silico' studies.
NGS analysis of TPO in 192 patients with CH revealed 3 different variations in 2 individuals (2/192, 1%). Sequencing other CH candidate genes in the patients with TPO variants revealed that patient 1 was homozygous for c.2422delT TPO mutation combined with double heterozygous DUOX2 pathogenic variants (p.R683L/p.L1343F) and patient 2 was triallelic for TPO pathogenic variants (p.R648Q/p.T561M/p.T561M). The present study identified a novel TPO variation c.1682C>T/p.T561M; and four known mutations: c.2422delT/p.C808Afs×24 and c.1943C>T/p.R648Q in TPO, c.2048G>T/p.R683L and c.4027C>T/p.L1343F in DUOX2.
Our study indicated that the prevalence of TPO mutations was 1% among studied Chinese patients with CH. More than two variations in one or more CH-associated genes can be found in a single patient, and may, in combination, affect the phenotype of the individual. A novel TPO variation c.1682C>T/p.T561M was found, thereby expanding the mutational spectrum of the gene.
据报道,人类甲状腺过氧化物酶(TPO)基因缺陷是先天性甲状腺功能减退症(CH)因激素合成障碍所致的病因之一。本研究旨在检测中国广西壮族自治区CH患者中TPO基因突变谱及患病率,并明确TPO基因分型与临床表型之间的关系。
采集中国广西壮族自治区192例CH患者的血样,从外周血白细胞中提取基因组DNA。通过二代测序(NGS)对包括TPO在内的10个常见CH相关基因的所有外显子及其外显子 - 内含子边界进行筛查。通过“电子”研究调查新型TPO突变的影响。
对192例CH患者的TPO进行NGS分析,在2例个体(2/192,1%)中发现3种不同变异。对TPO变异患者的其他CH候选基因进行测序发现,患者1为c.2422delT TPO突变纯合子,同时伴有双杂合DUOX2致病变异(p.R683L/p.L1343F),患者2为TPO致病变异的三等位基因(p.R648Q/p.T561M/p.T561M)。本研究鉴定出一种新型TPO变异c.1682C>T/p.T561M;以及4种已知突变:TPO基因中的c.2422delT/p.C808Afs×24和c.1943C>T/p.R648Q,DUOX2基因中的c.2048G>T/p.R683L和c.4027C>T/p.L1343F。
我们的研究表明,在研究的中国CH患者中,TPO突变的患病率为1%。在单个患者中可发现一个或多个CH相关基因存在两种以上变异,并且这些变异可能共同影响个体的表型。发现了一种新型TPO变异c.1682C>T/p.T561M,从而扩大了该基因的突变谱。